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Abstract 
Background & objectives: Introducing a nucleic acid test program is aimed to diagnose and reduces the risk of viral 
infection or transmission. DNA assay for HBV can detect infection in the windows period, chronic occult infection and 
can discriminate between active and inactive HBV infection. This cross-sectional study designed to diagnose, analyze 
HBV infection and to differentiate active from inactive infection based on viral DNA detection. Methods: Blood 
samples were collected from 256 patients previously diagnosed on the clinical ground as hepatitis B seropositive in 
Erbil Central Lab. The viral nucleic acid quantitative assessment was done for the collected samples using RT-PCR. Q-
square was performed for statistical analysis. Results: Out of 256 collected blood samples 93 (36.3%) showed HBV-
DNA positive titers above 50 IU/ml. Among positive subjects, 67 (72.04%) was categorized as inactive carriers (˂  
2000-20.000 IU/ml HBV-DNA titers). Conclusions: The data produced from this study confirmed the importance of 
the RT-PCR technique in sensitivity and reliability as a superior diagnostics tool specifically in differentiating active 
from inactive HBV carriers. 
1- Introduction 
Hepatitis B virus (HBV) is a worldwide risk health problem, about two billion people have HBV serologic markers 
[1]. On the clinical ground, more than 360 million people are chronically infected [2]. In many countries, molecular 
techniques have been introduced as routine screening methods [3]. Screening for HBV via DNA amplification is 
efficient in minimizing HBV transmission via blood and blood products [4]. Periodic monitoring of blood HBV-DNA 
is of paramount importance in the management of chronic hepatitis B infection [5]. Molecular techniques can be used 
for differentiation between active and inactive HBV infection. Active HBV carriers with high viral load is a remarkable 
risk factor for both incidence and mortality of HCC [6 ],[7],whereas inactive HBV carrier denotes the low rate of HBV 
reactivation, HCC, progressions to cirrhosis and good prognosis [8]. The viral genome is a 3.2 kb circular partially 
duplex DNA molecule with the circularity conserved by 5’ ends. The genome is made only from condensed coding 
regions with four open reading frames (ORFs) [9]. For quantification of HBV DNA laboratory measures how many 
units of the viral DNA are found in a ml of blood (international units per milliliter or IU/ml). The viral DNA levels 
range from thousands up to millions, referred as a high rate of HBV replication. However, levels–less than 2,000 IU/ml 
referred to as an “inactive” infection or undetectable [10] ,[ 11]. During HBV infection, markers can be detected in sera 
samples using immunoassays. For example, patient sera that contain anti-HBs indicates immunity from past infections 
or vaccinations, and a patient with anti-HBe antibodies in their sera is considered as a spontaneous resolution of 
infection or therapy-induced improvement [12 and 13]. One of the serological methods using for diagnosis of HBV is 
enzyme immune assays (EIAs). ELISA test is a qualitative serological test for the diagnosis of HBsAg human serum. 
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However, DNA amplification using RT-PCR is potentially a more sensitive assay [14]. RT-PCR for example used as a 
molecular technique for detection and quantification of the viral genome, which can also discriminate between active 
and inactive infection [15]. The aim of this study was to discriminate between active and inactive HBV infections based 
on DNA titers.  
2- Materials and Methods  
For this cross-sectional study, blood samples were collected from 256 patients suspected on the clinical pictures as 
viral hepatitis, referred to Erbil Central Laboratory, from June to September 2017 for HBV DNA screening. Some 
patients were referred because of a history of Jaundice confirmed serologically using HBs Ag testing. Other patients 
were referred as follow up for assessment of viral load and treatment response. Both sexes were included (154 males 
and 102 females); with age range between 20-60 years. This project was approved at the first site by the Scientific and 
Research Ethics Committee at the College of Health Sciences, Hawler Medical University/ Iraq. 
Five ml of venous blood were collected using EDTA tubes and centrifuged at 1000rpm for 5 minutes and patients’ 
plasma was separated. Viral HBV DNA was extracted from a 200uL aliquot of serum using a Qiagen mini blood kit 
(Qiagen, Hilden, Germany) according to manufacturer instructions. Viral loads of HBV DNA were estimated by RT-
PCR (HBV RG PCR Artus Germany).For RT-PCR reaction a 50µl reaction mixture was used, which contains: 30µl of 
Master-mix (Buffer, dNTP, primer, probe, and enzymes) and HBV RG inhibition control mixed with 20 µl of DNA 
template. HBV-Taq I forward primer: CAA CCT CCA ATC ACT CAC CAAC and HBV- Taq 2 reverse primer: ATA 
TGA TAA AAC GCC GCA GAC AC were used [16]. RT-PCR in which Rotorgene 3000 was then used to detect 
HBV-DNA according to the manufactures instructions. The RT-PCR cycling parameters consisted of denaturation at 
95ºC for 15 seconds, 55ºC for 30 seconds and 72ºC for 15 seconds. The results were considered positive if a signal was 
detected in cycling A FAM, whereas no signal detection indicated as negative results. The quantitation of HBV DNA 
was performed for all blood samples and the results were considered positive and significant if viral load was more than 
1×105 viral copies/ ml. Titers less than 50IU were considered as negative for HBV DNA. The screened results were 
categorized according to positive HBV DNA titers into inactive, gray zone and active carriers.  
3- Statistical Analysis 
For statistical analysis, SPSS 23.0 was used. HBV titers expressed as means ± SE. Comparisons between active and 
inactive carriers T-tests were depended. Comparisons between multiple groups were performed by ANOVA. P values ≤ 
0.05 was considered as statistically significant. 
4- Results  
The results of the present study delineated the frequency of HBV-DNA among screened patients. Accordingly, 
HBV-DNA was positive in 36% of the tested patients; the frequency of HBV-DNA positive results constituted 42% 
and 27% for males and females respectively (Table 1). The distribution of HBV-DNA titers revealed the highest 
positively rate at titer 101-500IU/ ml and ˃  20.000 IU/ml (20% and 23% respectively) (Table 2). On the other hand, 
Table (3) showing the distribution of means of HBV-DNA titers, and statistically the differences were highly 
significant (p ≤ 0.001). The discrimination of active and inactive HBV infection among HBV-DNA blood samples was 
based on three HBV-DNA titers (8). Thus, inactive carriers (≥ 50-2000 IU/ml); Gray zone carriers (2001-20.000 IU/ml) 
and active carriers (˃  20.000 IU/ml) were categorized among the total HBV-DNA positive blood screened (Table 4). 
Thus, the frequency of HBV infection as inactive, gray zone (as extended inactive) to active group revealed 46%, 21%, 
and 30% respectively. Table 5 delineated highly significant differences between the mean titers of HBV-DNA inactive 
and active carrier (p ≤ 0.05).   
 
Table 1: Frequencies of HBV DNA positivity according to the gender. 
Gender Positive PCR Negative PCR Total P Value 
Male  65 (42.20%) 89 (57.79%) 154 ≤0.001 
Female  28 (27.45%) 74 (72.54%) 102 
Total 93 (36.3232%) 163 (63.67%) 256 
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Table 2: Percentages of HBV DNA according to titer range among patients 
 
HBV DNA PCR titers IU/ml 
˂ 50 IU 50-100 101-500 501-1000 1001-2000 2001-20.000 ˃ 20.000 
21 
(18.42%) 
4 
(3.50%) 
23 
(20.17%) 
9 
(7.89%) 
9 
(7.89%) 
21 
(18.42%) 
27 
(23.68%) 
 
Table 3: Mean HBV DNA titers among positive patients screened. 
PCR titers IU/ml pValue 
≥ 50-100 n=4 101-500 
n=23 
501-1000 
n=9 
1001-2000 
n=9 
2001-20.000 
n=21 
˃ 20.000 
n=27 
 
 
0.001 
71.25 ± 5.66 284.60 ± 21.38 755.0 ±  39.95 1425.3 ± 70.95 3767.14 ±    
405.32 
120936819± 
36526296.47 
 
Table 4: Percentage of active and inactive HBV infection among patients according to titers. 
Inactive carriers Gray zone carriers Active carriers 
≥ 50-2000 IU/ ml 2001-20.000 IU/ ml ˃  20.000-990885600 IU/ ml 
45 (48.38 %) 21 (22.58%) 27 (29.03%) 
 
Table 5: Mean HBV DNA titers in active and inactive patients. 
    PCR HBV DNA titers PValue 
Inactive carriers 
n=66 
Active carriers 
n=27 
 
≤ 0.01 
1599.53 ± 225.70 120936819.9± 36526296.47 
 
 
5- Discussion 
The detection of HBV infection is vital for diagnosis, follow up the study and for controlling spread in 
community with the limited spectrum of disease range for acute to chronic, often progress to liver cirrhosis and HCC 
depends on the interplay between viral and host factors [17-19]. Two phases characterize the acute exposure to HBV 
namely immune-tolerant and immune reactive phase [8]. But some patients remain in an active carrier with serum level 
of HBV-DNA < 2000 IU/ml; while others progress to HBe antigen-negative chronic hepatitis B [20]; as HBe regarded 
as markers for HBV replication and increased risk of patient infectivity. The present study revealed HBV DNA 
positivity in 36.32% patients (previously diagnosed serologically) diagnosed on clinical pictures as HBV infection 
(Table 1). These results were disagreed with others who reported 60.5%, 71.4% and 82.2% as positive for HBV 
infection [21-23]. Of these patients, 66 (70.97%) were categorized as inactive carriers. While the remaining were active 
carriers (29.03%), with DNA viral titers >20,000 IU/ml (Table 5). The impact of genders revealed 42% males and 27% 
females HBV DNA positivity rate (P value ≤ 0.01) (Table 1), this was disagree with what reported by [23] and agree 
with [21]. Screening for HBV viral DNA amplification is efficient in minimizing HBV transmission via blood and 
blood products besides as a diagnostic tool [4]. Four phases characterize chronic hepatitis B (CHB) infection namely 
immune tolerant, immune clearance, immune control and immune escape [19]. These four phases in CHB infection 
neither take place sequentially [24] nor occur in all infected people. Of all 4 phases, only patients that require antiviral 
and immune modulators therapy those in either the immune clearance or immune escape phase [19]. Accordingly, the 
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selective quantitation using (RT-PCR assay is critical for assessment of serum HBV DNA levels after antiviral therapy; 
for HBV diagnosis; discrimination between active and inactive HBV infection and for the diagnosis of acute HBV 
infections [19 and 25]. This holds true for the patients in the present study because some were clinically suspected as 
viral hepatitis, and others were follow up that needs to discriminate of active from inactive and as treatment response. 
Especially the HBV DNA levels can shift from low or undetectable to >2,000,000 IU/mL [26] and some inactive 
carriers could occasionally have HBV DNA levels between 2000-20,000 IU/ml. Thus, single HBV DNA level between 
2,000-20,000 IU/ml categorized to be a “gray area” which can refer to both active CHB and inactive carriers [26]. In 
the present study, 21.64% patients were in the gray zone carriers (Table 4). Accordingly, clinicians should be aware of 
the importance and significance of serial HBV DNA measurements and lifelong follow-up to confirm maintenance of 
inactive carrier state [8]. A newly diagnostic criterion has been revised for inactive carrier based on detection of lower 
ALT upper limits of normal levels of 30 IU/ ml for men and 19 IU/ml for women [26]. But, still, the EASL 
acknowledges that inactive carriers might exist with DNA levels between 2,000-20,000 IU/ ml [20].    
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